Knowledge HQ

This study introduces NeoExpand, a platform to selectively expand TCR-engineered T cells against neoantigens while preserving stemness. G-Rex culture systems (including 24-well and 6-well formats and G-Rex 100 flasks) are referenced for executing cell activation and rapid expansion protocols.

This article describes a novel feeder cell-free method to activate and expand human CAR-NK cells using PMA and ionomycin. Large-scale manufacturing in G-Rex bioreactors, such as G-Rex 6-well plates, successfully supports high cell viability, comparable transduction, and significantly enhanced potency.

This protocol details ex vivo manufacturing of CAR-engineered human NK cells from peripheral blood. It optimizes immunomagnetic isolation, viral transduction, and cell expansion. G-Rex system devices, specifically G-Rex 6-well plates, are recommended to achieve robust NK cell expansion and high cell yields.

This study presents a robust, scalable, xeno-free protocol to differentiate human induced pluripotent stem cells into functional macrophages. Culturing myeloid progenitors in G-Rex bioreactors, including proposed scaling to G-Rex 10, 50, and 500 models, significantly optimizes cell yield and purity.

This study evaluates fratricide-resistant anti-CD7 CAR T-cells in acute myeloid leukemia. The therapy exhibits potent anti-leukemic activity with minimized fratricide of engineered cells. G-Rex is not referenced in this document.

This study presents the clinical development and GMP manufacturing of gene-edited, tacrolimus-resistant regulatory T cells (FKBP12KO-Tregs) to prevent organ transplant rejection. Tregs are cultured in G-Rex 10 and 100 bioreactors for robust clinical-scale expansion with high viability.

This study optimizes isolation, CRISPR-Cas9 knockout of SRC-3, and expansion of human regulatory T cells (Tregs) for adoptive cell therapy in solid tumors. Using G-Rex bioreactors, they achieved a 25-to-40-fold expansion rate, maintaining high FOXP3 expression and viability.

This study introduces Cas9-CLIPT, a method to efficiently integrate large transgenes (2-6 kb) into human T cells without restriction enzymes. It produces highly potent GD2 TRAC-CAR T cells with an enriched stem cell memory phenotype. G-Rex 6M well plates are referenced for cell cultivation post-electroporation.

This study describes 'metabolic priming' of GD2 TRAC-CAR T cells during manufacturing by activating them in glucose/glutamine-low medium and expanding in glucose/glutamine-high medium. This process enhances stem-like memory phenotypes and in vivo persistence. G-Rex6M plates are referenced for ex vivo cell expansion.

This study demonstrates that closed-system G-Rex bioreactors combined with Thermo Scientific Vios iDx CR CO2 incubators significantly reduce contamination risks. G-Rex bioreactors eliminate manual handling, feature a validated sterile fluid path, and expand cells safely in low-grade cleanrooms.

This study shows that treating CRISPR-engineered GD2 TRAC-CAR T cells with the class I HDAC inhibitor chidamide enhances their stem cell memory phenotype (CD62L+/CCR7+/IL-7Rα+) and in vivo persistence without increasing exhaustion. Technical support on the G-Rex system from ScaleReady is acknowledged.

This study outlines a rapid 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood. The process maintains high cell viability, transduction efficiency, and therapeutic potency. A G-Rex 10M vessel is explicitly used for the brief T-cell culture and expansion phase.